PILO, Maria Giulia
 Distribuzione geografica
Continente #
NA - Nord America 508
EU - Europa 230
AS - Asia 166
OC - Oceania 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
Totale 911
Nazione #
US - Stati Uniti d'America 503
CN - Cina 85
UA - Ucraina 83
IT - Italia 60
SG - Singapore 52
DE - Germania 39
ID - Indonesia 16
FI - Finlandia 14
CZ - Repubblica Ceca 9
SE - Svezia 9
CA - Canada 5
GB - Regno Unito 4
TR - Turchia 4
AU - Australia 3
FR - Francia 3
IR - Iran 3
AT - Austria 2
BE - Belgio 2
DZ - Algeria 2
KR - Corea 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
DK - Danimarca 1
EU - Europa 1
IN - India 1
IQ - Iraq 1
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
Totale 911
Città #
Chandler 154
Jacksonville 55
Singapore 44
Sassari 35
Princeton 34
Nanjing 20
Ashburn 18
Mountain View 15
Wilmington 14
Woodbridge 13
Dearborn 11
Ann Arbor 10
Beijing 10
Houston 10
New York 10
Brno 9
Munich 9
Fairfield 8
Helsinki 7
Jinan 6
Nanchang 6
Santa Clara 6
Shenyang 5
Boardman 4
Cagliari 4
Guangzhou 4
Izmir 4
Jiaxing 4
Monmouth Junction 4
Norwalk 4
Seattle 4
Toronto 4
Changsha 3
Hebei 3
Ningbo 3
Algiers 2
Ardabil 2
Augusta 2
Brussels 2
Cambridge 2
Como 2
Dallas 2
Seoul 2
Shanghai 2
Tianjin 2
Vienna 2
Wuxi 2
Alghero 1
Andover 1
Baghdad 1
Carbonia 1
Florence 1
Fremont 1
Fuzhou 1
Hangzhou 1
Hefei 1
Jiangmen 1
Kunming 1
Lanzhou 1
Leawood 1
Marrùbiu 1
Melbourne 1
Milan 1
Motru 1
Mumbai 1
Osaka 1
Ottawa 1
Redwood City 1
Rockville 1
San Mateo 1
Sydney 1
Taizhou 1
Tappahannock 1
Utrecht 1
Washington 1
Xi'an 1
Zhengzhou 1
Totale 608
Nome #
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 93
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 76
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 70
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 69
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 63
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 63
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 60
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 56
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade 51
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 48
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 46
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 46
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 42
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 41
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 41
La Completa inibizione della via di segnale mTORC1 è necessaria per la soppressione dell’epatocancerogenesi indotta dall’iperespressione dei protooncogeni AKT e N-Ras nel topo 31
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease 24
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 24
Totale 944
Categoria #
all - tutte 5.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.540


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202093 0 0 0 0 12 9 25 1 19 5 22 0
2020/2021175 16 0 65 1 17 2 20 0 21 17 15 1
2021/202279 3 0 0 2 0 0 2 2 6 3 23 38
2022/2023257 28 35 6 39 20 35 0 31 43 2 10 8
2023/202494 12 8 4 1 26 7 1 12 0 3 4 16
2024/202593 7 10 24 29 23 0 0 0 0 0 0 0
Totale 944